Join to View Full Profile
1051 Riverside DrNew York, NY 10032
Phone+1 646-774-6315
Dr. Shulman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Northwell HealthResidency, 2012 - 2016
Rutgers New Jersey Medical SchoolClass of 2012
Certifications & Licensure
NY State Medical License 2014 - 2027
NJ State Medical License 2017 - 2025
American Board of Psychiatry and Neurology Psychiatry- American Board of Psychiatry and Neurology Addiction Psychiatry
Publications & Presentations
PubMed
- Effects of randomization to buprenorphine or naltrexone for OUD on cannabis use outcomes: A secondary analysis of the X:BOT trial.Matisyahu Shulman, Tse-Hwei Choo, Kaitlyn Ohrtman, Martina Pavlicova, John Rotrosen
Drug and Alcohol Dependence. 2025-03-01 - Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).Matisyahu Shulman, Sarah Meyers-Ohki, Patricia Novo, Scott Provost, Kaitlyn Ohrtman
Contemporary Clinical Trials. 2025-03-01 - 3 citationsComparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients.Rachael K Ross, Edward V Nunes, Mark Olfson, Matisyahu Shulman, Noa Krawczyk
Addiction. 2024-11-01
Press Mentions
Rapid Procedure Noninferior for Extended-Release Naltrexone InitiationMay 10th, 2024- Faster Approach for Starting Extended-Release Naltrexone to Treat Opioid Use Disorder Shown EffectiveMay 9th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
